Latest Gilead Sciences Stories
ATLANTA, Sept. 19, 2012 /PRNewswire-USNewswire/ -- Amgen CEO Kevin Sharer, at $1.75 million in his final year before retirement, led the list of highest-salaried biotechnology executives in 2011, followed by John Martin, Gilead Sciences CEO, with $1.42 million, although Martin topped all executives in total compensation, with $54.58 million, to lead the "Millionaire's Club," according to data in the BioWorld Executive Compensation Report 2013: Trends in C-Level Salaries and Benefits...
VANCOUVER, British Columbia, Sept. 18, 2012 /PRNewswire/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Gilead Sciences (NASDAQ:GILD), Office Depot (NYSE:ODP), Threshold (NASDAQ:THLD), American Capital Agency (NASDAQ:AGNC), ConocoPhillips (NYSE:COP), and Potash (NYSE:POT). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full...
Singapore, Sept 6, 2012 - (ACN Newswire) - Scientists from A*STAR's Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London(1), discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.This discovery by the team of scientists led by Professor...
Connie K. Ho for redOrbit.com – Your Universe Online The Food and Drug Administration (FDA) recently approved the sale and distribution of Stribild, an HIV medication that includes four different drugs in one pill. The FDA believes that Stribild offers complete treatment for infections related to HIV. The cost of the drug is about $28,500 for a year’s supply, which gives manufacturer Gilead Sciences Inc. unlimited pricing power as the company retains ownership of all the ingredients...
Connie K. Ho for redOrbit.com – Your Universe Online U.S. health officials recently issued recommendations to physicians with heterosexually-active patients considering the use of Truvada, a pill that can reduce the risk of the HIV virus for people engaging in sexual intercourse. The pill was originally only advised to be given to high-risk gay and bisexual men. The news is of particular interest to straight people who make up 25% of new HIV cases every year, according to the Centers...
PITTSBURGH and HYDERABAD, India, Aug. 2, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the establishment of a new agreement between its subsidiary Mylan Laboratories Limited and Gilead Sciences Inc. Under this agreement, Mylan has licensed the rights to produce and market generic versions of Gilead HIV/AIDS therapies containing Emtricitabine, including single and fixed-dose combinations. Emtricitabine is marketed by Gilead under the brand name Emtriva(®), and a...
VANCOUVER, British Columbia, July 30, 2012 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Citigroup (NYSE:C), Exxon Mobil (NYSE:XOM), Gilead Sciences (NASDAQ:GILD), Green Dot (NYSE:GDOT), Research In Motion (NASDAQ:RIMM), and Acme Packet (NASDAQ:APKT). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to...
BELLEVILLE, ON, July 30, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that Mr. James Rae has been appointed as independent Chairman of the Board of Directors. The Chairman role has been performed by President & CEO, Mr. Graeme McRae. Mr. Rae takes over the role immediately. Mr. Rae has been the CEO of London, Ontario-based Viron Therapeutics Inc. since 2007. He...
RESEARCH TRIANGLE PARK, N.C., July 24, 2012 /PRNewswire/ -- Chimerix, Inc. today announced the execution of a license agreement granting Merck, known as MSD outside the United States and Canada, exclusive worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate currently being evaluated to treat HIV infection. Under the terms of the agreement, Merck receives an exclusive worldwide license and will be responsible for development and commercialization of...
Safety, tolerability study to enroll MSM in the United States and Puerto Rico Scientists are launching the first clinical trial to test whether drug regimens containing maraviroc, a medication currently approved to treat HIV infection, are also safe and tolerable when taken once daily by HIV-uninfected individuals at increased risk for acquiring HIV infection. The eventual goal is to see if the drug regimens can reduce the risk of infection. The trial involves a strategy known as...
